Shawn D. Doran

1.4k total citations
20 papers, 747 citations indexed

About

Shawn D. Doran is a scholar working on Oncology, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Shawn D. Doran has authored 20 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Shawn D. Doran's work include Peptidase Inhibition and Analysis (7 papers), Diabetes Treatment and Management (7 papers) and Drug Transport and Resistance Mechanisms (5 papers). Shawn D. Doran is often cited by papers focused on Peptidase Inhibition and Analysis (7 papers), Diabetes Treatment and Management (7 papers) and Drug Transport and Resistance Mechanisms (5 papers). Shawn D. Doran collaborates with scholars based in United States, Sweden and United Kingdom. Shawn D. Doran's co-authors include Ernesto Callegari, Cuiping Chen, Frederick Nelson, Stacey L. Becker, John P. Gibbs, Jianhua Liu, Bill J. Smith, Angela C. Doran, Natilie Hosea and Julie Cianfrogna and has published in prestigious journals such as Nature Communications, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Shawn D. Doran

20 papers receiving 718 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shawn D. Doran United States 16 272 213 153 149 106 20 747
Norman Huebert United States 21 356 1.3× 144 0.7× 283 1.8× 103 0.7× 85 0.8× 40 1.1k
Constance Farley United States 13 283 1.0× 157 0.7× 110 0.7× 109 0.7× 175 1.7× 19 1.2k
Loren Berry United States 13 284 1.0× 132 0.6× 190 1.2× 44 0.3× 108 1.0× 20 694
James Ficorilli United States 17 573 2.1× 270 1.3× 222 1.5× 52 0.3× 372 3.5× 20 1.3k
Madeleine Antonsson Sweden 14 280 1.0× 333 1.6× 133 0.9× 71 0.5× 24 0.2× 20 1.1k
Maria Beconi United States 18 312 1.1× 126 0.6× 147 1.0× 144 1.0× 81 0.8× 30 791
Tadayuki Takashima Japan 24 257 0.9× 473 2.2× 82 0.5× 67 0.4× 52 0.5× 39 1.1k
Nalini Sadagopan United States 15 530 1.9× 144 0.7× 213 1.4× 93 0.6× 107 1.0× 20 1.4k
Kristian T. Hansen Denmark 12 256 0.9× 157 0.7× 200 1.3× 45 0.3× 91 0.9× 18 666
Kerry L. Spear United States 20 488 1.8× 155 0.7× 233 1.5× 293 2.0× 57 0.5× 31 984

Countries citing papers authored by Shawn D. Doran

Since Specialization
Citations

This map shows the geographic impact of Shawn D. Doran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shawn D. Doran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shawn D. Doran more than expected).

Fields of papers citing papers by Shawn D. Doran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shawn D. Doran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shawn D. Doran. The network helps show where Shawn D. Doran may publish in the future.

Co-authorship network of co-authors of Shawn D. Doran

This figure shows the co-authorship network connecting the top 25 collaborators of Shawn D. Doran. A scholar is included among the top collaborators of Shawn D. Doran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shawn D. Doran. Shawn D. Doran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stepan, Antonia F., Tuan P. Tran, Christopher J. Helal, et al.. (2018). Late-Stage Microsomal Oxidation Reduces Drug–Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189. ACS Medicinal Chemistry Letters. 9(2). 68–72. 25 indexed citations
2.
Takano, Akihiro, Laigao Chen, Sangram Nag, et al.. (2018). Quantitative Analysis of 18F-PF-06684511, a Novel PET Radioligand for Selective β-Secretase 1 Imaging, in Nonhuman Primate Brain. Journal of Nuclear Medicine. 60(7). 992–997. 6 indexed citations
3.
Zhang, Lei, Laigao Chen, Jason K. Dutra, et al.. (2018). Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain. Journal of Medicinal Chemistry. 61(8). 3296–3308. 15 indexed citations
4.
Zuhl, Andrea M., Charles E. Nolan, Michael A. Brodney, et al.. (2016). Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors. Nature Communications. 7(1). 13042–13042. 59 indexed citations
5.
Griffith, David A., Daniel W. Kung, William P. Esler, et al.. (2014). Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes. Journal of Medicinal Chemistry. 57(24). 10512–10526. 60 indexed citations
6.
Sharma, Raman, Hao Sun, David W. Piotrowski, et al.. (2012). Metabolism, Excretion, and Pharmacokinetics of ((3,3-Difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a Dipeptidyl Peptidase Inhibitor, in Rat, Dog and Human. Drug Metabolism and Disposition. 40(11). 2143–2161. 24 indexed citations
7.
DeNinno, Michael P., Stephen W. Wright, John B. Etienne, et al.. (2012). Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes. Bioorganic & Medicinal Chemistry Letters. 22(17). 5721–5726. 22 indexed citations
8.
DeNinno, Michael P., Stephen W. Wright, Michael Visser, et al.. (2011). 1,5-Substituted nipecotic amides: Selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability. Bioorganic & Medicinal Chemistry Letters. 21(10). 3095–3098. 22 indexed citations
9.
Andrews, Kim, David A. Beebe, John W. Benbow, et al.. (2011). 1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters. 21(6). 1810–1814. 16 indexed citations
10.
McHardy, Stanton F., Steven D. Heck, Sara Guediche, et al.. (2011). Discovery of CP-866,087, a mu opioid receptor antagonist for the treatment of alcohol abuse and dependence. MedChemComm. 2(10). 1001–1001. 20 indexed citations
11.
Ammirati, Mark, Kim Andrews, Dennis E. Danley, et al.. (2009). (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: A potent, selective, orally active dipeptidyl peptidase IV inhibitor. Bioorganic & Medicinal Chemistry Letters. 19(7). 1991–1995. 33 indexed citations
12.
Humphries, Paul S., John W. Benbow, Paul D. Bonin, et al.. (2009). Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists. Bioorganic & Medicinal Chemistry Letters. 19(9). 2400–2403. 47 indexed citations
13.
Benbow, John W., Jiri Aubrecht, David A. Beebe, et al.. (2009). Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of Type 2 diabetes. Bioorganic & Medicinal Chemistry Letters. 19(8). 2220–2223. 6 indexed citations
14.
Wright, Stephen W., Mark Ammirati, Kim Andrews, et al.. (2007). (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: Synthesis, in vitro, in vivo, and X-ray crystallographic characterization. Bioorganic & Medicinal Chemistry Letters. 17(20). 5638–5642. 13 indexed citations
15.
Corbett, Jeffrey W., Kenneth J. DiRico, Brian P. Boscoe, et al.. (2007). Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(24). 6707–6713. 20 indexed citations
16.
Liu, Xingrong, Bill J. Smith, Cuiping Chen, et al.. (2006). Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration. Drug Metabolism and Disposition. 34(9). 1443–1447. 129 indexed citations
17.
Wright, Stephen W., Mark Ammirati, Kim Andrews, et al.. (2006). cis-2,5-Dicyanopyrrolidine Inhibitors of Dipeptidyl Peptidase IV:  Synthesis and in Vitro, in Vivo, and X-ray Crystallographic Characterization. Journal of Medicinal Chemistry. 49(11). 3068–3076. 28 indexed citations
18.
Liu, Xingrong, Bill J. Smith, Cuiping Chen, et al.. (2005). Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding. Journal of Pharmacology and Experimental Therapeutics. 313(3). 1254–1262. 136 indexed citations
19.
Lowe, John, Robert A. Volkmann, Steven D. Heck, et al.. (1999). A new class of selective and potent inhibitors of neuronal nitric oxide synthase. Bioorganic & Medicinal Chemistry Letters. 9(17). 2569–2572. 15 indexed citations
20.
Bauer, John Anthony, Jeffrey A. Wald, Shawn D. Doran, & David M. Soda. (1994). Endogenous nitric oxide in expired air: Effects of acute exercise in humans. Life Sciences. 55(24). 1903–1909. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Norman Huebert Breakdown of academic impact, for papers by Constance Farley Breakdown of academic impact, for papers by Loren Berry Breakdown of academic impact, for papers by James Ficorilli Breakdown of academic impact, for papers by Madeleine Antonsson Breakdown of academic impact, for papers by Maria Beconi Breakdown of academic impact, for papers by Tadayuki Takashima Breakdown of academic impact, for papers by Nalini Sadagopan Breakdown of academic impact, for papers by Kristian T. Hansen Breakdown of academic impact, for papers by Kerry L. Spear
Rankless by CCL
2026